SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Zacks11-28 00:31

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486380364?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-11-28 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486380364","market":"us","top_or_hot":-1,"title":"SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies","media":"Zacks","content":"<div>\n<p>Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/srpt-inks-11b-licensing-deal-163100788.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/srpt-inks-11b-licensing-deal-163100788.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/srpt-inks-11b-licensing-deal-163100788.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://finance.yahoo.com/news/srpt-inks-11b-licensing-deal-163100788.html","article_id":"2486380364","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486380364","pubTimestamp":1732725060,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in muscle, central nervous system  and rare pulmonary disorders.Arrowhead will remain responsible for the ongoing clinical studies. Once these studies are complete, Sarepta will assume responsibility for the later stages of development.Sarepta will assume responsibility for three preclinical assets following the completion of the investigational new drug -enabling activities by Arrowhead. These programs target spinocerebellar ataxia type 1, spinocerebellar ataxia type 3 and Huntington's disease.As part of this deal, th","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","CNS":"科恩-斯蒂尔斯金融","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4007":"制药","RHHBY":"罗氏控股","03165":"华夏欧优股对冲","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","ARWR":"Arrowhead Research Corporation","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4135":"资产管理与托管银行","SRPT":"Sarepta Therapeutics","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"SRPT与Arrowhead签署价值11B美元的罕见基因疗法许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNS":1,"RHHBY":1,"SRPT":1,"ARWR":0.9,"03165":0.6},"content_text":"Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.\nARWR Deal Expands Sarepta’s Pipeline\nPer the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical development. These programs are being developed against a broad range of genetic diseases in muscle, central nervous system (CNS) and rare pulmonary disorders.\nEach of the four clinical programs is currently being evaluated by Arrowhead in separate phase I/II studies targeting different diseases. The first is ARO-DUX4, which is being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), while ARO-DM1 is being developed to treat myotonic dystrophy type 1 (DM1). The remaining candidates, ARO-MMP7 and ARO-ATXN2, are being developed to treat idiopathic pulmonary fibrosis (IPF) and spinocerebellar ataxia 2 (SCA2) indications, respectively.\nArrowhead will remain responsible for the ongoing clinical studies. Once these studies are complete, Sarepta will assume responsibility for the later stages of development.\nSarepta will assume responsibility for three preclinical assets following the completion of the investigational new drug (IND)-enabling activities by Arrowhead. These programs target spinocerebellar ataxia type 1, spinocerebellar ataxia type 3 and Huntington's disease.\nAs part of this deal, the companies have also formed a discovery collaboration under which Sarepta will select six targets across skeletal muscle, cardiac and CNS areas, and Arrowhead will develop and deliver IND-ready constructs for those targets.\nFinancial Terms of the Sarepta-Arrowhead Deal\nIn exchange for acquiring these rights, Sarepta will make an upfront payment of $500 million plus an equity investment of $325 million in Arrowhead’s common stock. The company will also pay $250 million in annual installments over the next five years.\nPer Arrowhead, it has the potential to earn an additional $300 million through near-term clinical trial enrollment-related milestone payments. It is also eligible for future milestone payments of up to $10 billion, as well as royalties on product sales.\nSarepta also clarified that it will fund the deal with its existing cash balance and has no plans to raise additional capital. The deal is expected to close early next year, subject to customary rules and regulations.\nOther Announcements by SRPT\nThe company’s president and CEO, Doug Ingram, is set to join Arrowhead’s board of directors.\nAlongside the above news, Sarepta also announced that its board of directors has authorized a share repurchase program of up to $500 million of the company’s outstanding common stock over the next 18 months.\nSRPT Stock Performance\nWall Street was impressed with Sarepta’s licensing deal. If the deal is successfully closed, it would add potential therapies that not only complement the company’s pipeline of muscular dystrophies but also expand into new indications.\nSome analysts also opined that the company financing the deal with the existing cash balance and coming out with a new buyback program illustrates management’s confidence in the commercial potential of its currently marketed therapies, especially the recently approved DMD gene therapy Elevidys.\nYear to date, Sarepta Therapeutics’ shares have risen 35.3% against the industry’s 7.9% decline.\nImage Source: Zacks Investment Research\nSarepta’s Strong Commercial Portfolio\nSarepta’s commercial portfolio includes three approved RNA-based PMO therapies — Exondys 51, Vyondys 53 and Amondys 45 — and the one-shot gene therapy Elevidys, all targeting DMD indication.\nCurrently, Elevidys is the first and only one-shot gene therapy for DMD in the United States. Since its commercial launch last year in June, the gene therapy has demonstrated blockbuster potential. Sarepta has added around $437 million in product sales in the first nine months of 2024. In comparison, the therapy generated over $200 million in sales last year.\nElevidys has been developed by Sarepta in collaboration with pharma giant Roche RHHBY. Sarepta and Roche entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, RHHBY has exclusive rights to launch and commercialize Elevidys in ex-U.S. markets.\nApart from Elevidys, Sarepta has three other therapies in its commercial portfolio targeting the DMD patient population. Exondys 51 is the first approved disease-modifying therapy for DMD in the United States as well as the company’s first product to receive marketing approval. Exondys 51 recorded impressive sales growth in the past few quarters despite the COVID-19 pandemic. Vyondys 53 and Amondys 45 have also seen strong demand since their launch. Per management, these three drugs have the potential to address nearly a third of all patients with DMD in the United States.\nManagement is also gearing up to submit a regulatory filing with the FDA next year seeking approval for gene therapy candidate SRP-9003 in patients with limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4, or beta sarcoglycanopathy).\n\nSarepta Therapeutics, Inc. Price\n\nSarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote\n\nSRPT’s Zacks Rank\nSarepta Therapeutics currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nSarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486380364"}